Stockwinners Market Radar for February 06, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EST Cathie Wood's ARK Investment bought 15K shares of Tesla today

19:11 EST Snap CFO says can level out at cost structure that scale well to profitability - Says: "As I look forward to Q1, number one, we've seen a big increase in infrastructure costs in 2023. On the order of magnitude of about $100 million of quarterly run rate of higher infrastructure costs, and that's led to the rather significant increases in improper DOW. You saw that start to slow down as we went through the back half of 2023 and into Q4 of 2023 in terms of the sequential increase in the infrastructure for DAU and really look for that to continue to slow down or level off here as we move into Q1. And that's going to give us the opportunity to make progress against our medium- and long-term margin targets, given infrastructure is the biggest element of the cost of revenue side of things."

19:04 EST Snap CEO says not expecting further decline in North America DAU in Q1 - CEO Evan Spiegel says: "As we look at North America, in the fourth quarter, that decline was mostly an artifact of rounding. We're not expecting a further decline in North America in Q1. I do think overall, though, there is an opportunity for us to invest more in growth in North America and Europe. Over the past 5 to 7 years, we've really focused on our Android product and growth in emerging markets. That's really about attracting a large volume of new users. I think in places like North America and Europe, we can do a better job on iOS and really on resurrecting people who tried Snapchat or who aren't coming into the service as often or when they come back to receive a message from their friends, helping them onboard to our other different features. So that's going to be an increasing focus for us, and we'll be investing more there over the coming years." Comments taken from Q4 earnings conference call.

18:35 EST Chipotle CEO: Customers continue to see us as a terrific value - In an interview on CNBC's Mad Money, Brian Niccol said Q4 comps were driven by transactions. The company is going to drive harder and harder to increase throughput, he noted. The digital experience is better than ever. He believes the company can double its restaurant number to 7,000 in the long term. Employee turnover is the lowest it has been in years, he added.

17:38 EST Ford sees EVs about 40% of CapEx in FY24 - Sees $2B benefit from cost reduction initiatives in FY24 which offsets higher labor and major product refresh actions. Sees lower industry pricing; Non-recurrence of UAW strike; Flat to modest U.S. industry growth of 16M-16.5M.

17:32 EST Triumph Group awarded five-year contract from Asia Pacific operator - Triumph Group "announced that its TRIUMPH Product Support business in Chonburi, Thailand has been awarded a five-year contract from an Asia Pacific operator to provide maintenance, repair and overhaul services. The award includes MRO services for CF6-80C2 nacelles over multiple Boeing fleets. TRIUMPH has extensive experience servicing CF6 nacelles and a large portfolio of cost-effective repairs to draw upon."

17:23 EST Ford expects hybrid sales up 40% in FY24 - Says underlying business is getting better. Says solid conversion from profit to cash. Says getting much more disciplined with capital. Says "nowhere near" earnings potential for the company. Says overall EV strategy "has never been more relevant." Says will focus on trucks and vans. Says all EV teams "ruthlessly focused" on cost. Expects overall EV business to grow in 2024. Comments taken from Q4 earnings conference call.

17:13 EST ESPN, FOX and Warner Bros. Discovery confirm forming streaming sports JV - ESPN, a subsidiary of The Walt Disney Company (DIS), FOX (FOXA, FOX) and Warner Bros. Discovery (WBD) have reached an understanding on principal terms to form a new Joint Venture to build an innovative new platform to house a compelling streaming sports service. The platform brings together the companies' portfolios of sports networks, certain direct-to-consumer sports services and sports rights - including content from all the major professional sports leagues and college sports. The formation of the pay service is subject to the negotiation of definitive agreements amongst the parties. The offering, scheduled to launch in the fall of 2024, would be made available directly to consumers via a new app. Subscribers would also have the ability to bundle the product, including with Disney+, Hulu and/or Max. The platform would aggregate content to offer fans an extensive, dynamic lineup of sports content, aiming to provide a new and differentiated experience to serve sports fans, particularly those outside of the traditional pay TV bundle. By subscribing to this focused, all-in-one premier sports service, fans would have access to the linear sports networks including ESPN, ESPN2, ESPNU, SECN, ACCN, ESPNEWS, ABC, FOX, FS1, FS2, BTN, TNT, TBS, truTV, as well as ESPN+.

17:01 EST Range Resources reports Q4 production average 2,207 Mmcfe per day - Range Resources announced Q4 expectations for production and pricing with Q4 production averaging approximately 2,207 Mmcfe per day. In addition, Range realized $8.0M in contingent derivative settlement gains in Q4. Q4 daily natural gas production averaged approximately 1,540 Mmcf per day. The average natural gas realization, including the impact of basis hedges, was $2.40 per mcf, a (48c) per mcf differential to NYMEX. The average natural gas price, including all settled hedges, was $2.68 per mcf. Q4 daily NGL production averaged approximately 104,038 barrels per day. NGL realizations were $24.91 per barrel, approximately $2.42 above the Mont Belvieu weighted equivalent. Q4 daily oil and condensate production averaged approximately 7,136 barrels per day. Crude oil and condensate price realizations, before realized hedges, averaged $67.72 per barrel, approximately $10.56 below WTI. The average condensate price, including settled hedges, was $63.42 per barrel.

17:01 EST VF Corp. says CFO Matt Pattuck stepping down - Backs FY24 free cash flow view $600M Says results were impacted by cyber security event in December. Says cybersecurity event had 4c-5c impact to EPS. Says expects further reductions in inventory. Says expects actual gross savings in FY24 to be $60M. Says results in Q3 were challenged. Comments and guidance taken from Q3 earnings conference call.

16:45 EST Chipotle reports Q4 operating margin 14.4%, up from 13.6% last year - Restaurant level operating margin was 25.4%, an increase of 140 basis points. Opened 121 new restaurants with 110 locations including a Chipotlane.

16:42 EST Jamf announces 'immediate support' for Apple Vision Pro - Jamf (JAMF) announced it is first to market with support for Apple Vision Pro (AAPL) adding this powerful new endpoint to its Apple-first, Apple-best security and access products, Jamf Protect and Jamf Connect. With the introduction of MDM support in visionOS 1.1 beta, announced today by Apple, Vision Pro will soon include the key foundations for deploying and leveraging an enterprise-grade device at scale. Jamf will be working alongside Apple to support MDM in Vision Pro. "Jamf has a 20-year history of innovating at the speed of Apple. It's what our customers expect, so we are proud to announce our first-to-market support for Vision Pro in Jamf Protect and Jamf Connect. We are looking forward to helping organizations easily and safely explore the endless possibilities of Vision Pro in business contexts that require extra security and connectivity that go beyond the needs of a typical consumer use case," said Henry Patel, Chief Strategy Officer at Jamf...As Vision Pro MDM support becomes generally available from Apple, Jamf will be working to enable early adopters to extend their early Jamf Connect and Jamf Protect implementation to leverage Jamf Pro to achieve Trusted Access, where only authorized users on enrolled and safe devices can access company data

16:38 EST Atmos Energy raises quarterly dividend 8.8% to 80.5c per share - Atmos Energy said its Board of Directors increased the quarterly dividend 8.8% to 80.5c per common share. The indicated annual dividend for fiscal 2024 is $3.22.

16:35 EST Yum China reports Q4 restaurant margin expanded to 10.7% - Restaurant margin expanded to 10.7%. Excluding items affecting comparability at the restaurant level - the impact from temporary relief and VAT deduction benefits in both years, restaurant margin expanded 170 basis points.

16:33 EST Yum China steps up 2024 share repurchases to $1.25B - The company plans to repurchase $1.25B of its common stock in 2024, through open market transactions in the U.S. and Hong Kong.

16:32 EST Midland States boosts dividend 3.3% to 31c per share - Midland States Bancorp, announced that its Board of Directors declared a quarterly cash dividend of 31c per share of its common stock, an increase of 3.3% from the previous quarterly cash dividend of 30c per share. The dividend is payable on February 23 to all shareholders of record as of the close of business on February 16 . The Board of Directors also declared a cash dividend of $0.4844 per depository share on its 7.75% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A. The dividend will be payable on April 1, 2024 to stockholders of record as of March 15, 2024. Jeffrey G. Ludwig, President and Chief Executive Officer of the Company, said, "This dividend declaration represents the 24th consecutive year that Midland States Bancorp has increased its quarterly cash dividend. We are pleased that our financial performance and prudent balance sheet management enables us to continuing increasing the amount of capital that we return to shareholders through our quarterly dividend while also retaining a sufficient amount of capital to increase our capital ratios to better support the continued growth of our franchise."

16:24 EST Amgen sees more than a dozen significant pipeline milestones in 2024 - "2023 was another year of performance and progress for our company," said Robert Bradway, chairman and CEO. "Our marketed products are reaching many more patients around the world, and we anticipate more than a dozen significant pipeline milestones in 2024."

16:22 EST Paramount Group modifies, extends loan at One Market Plaza - Paramount Group announced that, together with its joint venture partner, it has modified and extended the existing mortgage loan at One Market Plaza, a 1.6 million square-foot two-building trophy asset in the South Financial District of San Francisco. The existing $975 million loan, which bears interest at a fixed rate of 4.03%, was scheduled to mature on February 6, 2024. In connection with the modification, the loan balance was reduced to $850 million, following a $125 million paydown by the joint venture. The modified loan bears interest at a fixed rate of 4.08% and matures in February 2027 and has an option to extend for an additional year, subject to certain conditions. "We are happy to announce the successful completion of this loan modification in a challenging capital markets environment. This transaction is a not only a testament to the quality of the asset, but also a testament to the quality of the sponsorship and its commitment to the asset," said Wilbur Paes, Chief Operating Officer, Chief Financial Officer, and Treasurer of Paramount.

16:19 EST Prudential names Yanela Frias CFO - Prudential Financial announced that Yanela Frias, president of Group Insurance, has been appointed executive vice president and CFO, effective March 15, 2024, succeeding Ken Tanji. Frias will join the executive leadership team as an executive officer and report to Robert Falzon, vice chair of Prudential. Tanji will remain with the company through Sept. 30, 2024, to ensure a smooth transition. "Ken has played an important role in Prudential's success, holding a variety of finance leadership positions over his tenure with the company and, most recently, in directing the company's financial strategy. Ken made meaningful contributions as our CFO, including leading de-risking and capital release transactions, delivering on expense objectives, and successfully steering the company through the financial challenges of the pandemic and ensuing market volatility. On behalf of the Board of Directors and management team, I want to thank him for his 35 years of distinguished service and his many contributions and commitment to Prudential," said Charles Lowrey, chairman and CEO of Prudential Financial.

16:16 EST Snap down 28% after Q4 report, Q1 guidance - Snap shares are down $4.85, or 28%, to $12.60 in after-hours trading.

16:11 EST Chipotle sees FY24 comparable restaurant sales growth mid single digits - For 2024, management is anticipating the following: Full year comparable restaurant sales growth in the mid-single digit range; 285 to 315 new restaurant openings, which assumes developer, permit, inspection, and utility delays do not worsen; An estimated underlying effective full year tax rate between 25% and 27% before discrete items.

16:08 EST Northern Oil and Gas raises quarterly dividend 18% to 40c per share - Northern Oil and Gas announced the declaration of a dividend on the Company's common stock and provided an update on current hedging positions. NOG's Board of Directors has declared a cash dividend in the amount of $0.40 per share, the planned quarterly level for 2024 as previously disclosed. The dividend is payable on April 30, 2024, to stockholders of record as of the close of business on March 28, 2024. "We continue to deliver on our plan to generate strong free cash flow that can be dynamically allocated to create value for our investors," commented Chad Allen, NOG's Chief Financial Officer. "At the same time, through our practice of systematic hedging, we are protecting our underwritten returns. With an improved hedge profile, strong balance sheet and significant free cash flow, we have great options to deliver growth and value in multiple forms. Given our attractive current dividend yield of approximately 5% and a moderated commodity price environment, we plan to prioritize further growth investments and potential share repurchases as we seek to maximize total shareholder return in 2024."

16:07 EST Exelon names Mike Innocenzo COO - Exelon announced that Mike Innocenzo, currently president and chief executive officer of Exelon subsidiary PECO, has been promoted to executive vice president and chief operating officer of Exelon, reporting to Exelon President and Chief Executive Officer Calvin Butler. Innocenzo will oversee all utility operations and the CEOs of BGE, ComEd, PECO and PHI will report to him. He will also be responsible for the Cyber & Information Security Services, Corporate Physical Security, IT, Safety, Supply, Training and Transmission Strategy & Compliance organizations. Dave Velazquez, currently Exelon executive vice president of Utility Operations and Technology, will succeed Innocenzo as president and chief executive officer of PECO, Pennsylvania's largest electric and natural gas delivery company serving nearly 1.7 million electric customers and more than 548,000 natural gas customers in southeastern Pennsylvania. "As we focus on leading an equitable energy transformation for our customers and communities, making a positive impact begins with the talent and experience of our team," said Butler. "We are pleased to have Mike Innocenzo, who has spent his career delivering operational excellence at PECO, bring his expertise to overseeing operations across Exelon. Mike will build on the top-tier performance levels our customers have come to expect. Similarly, we have a high caliber, respected industry leader in Dave Velazquez, with experience leading utilities, to continue PECO's advance toward best-in-class service. Both leaders are a testament to the depth of experience at Exelon." Exelon's Executive Vice President and Chief Human Resources Officer (CHRO) Amy Best has announced she will retire in May. Best has been with the company for 32 years, serving as Exelon's CHRO since 2012. During her tenure, Exelon has been widely recognized for its commitment to DEI, pay equity and family leave policies. Denise Galambos will succeed Best as senior vice president and Exelon's CHRO. Denise currently serves as Baltimore Gas and Electric's (BGE) senior vice president of Customer Operations.

16:05 EST Gilead raises quarterly dividend 2.7% to 77c per share - Gilead Sciences announced that the company's Board of Directors has declared an increase of 2.7% in the company's quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval.

15:55 EST Anheuser-Busch 'not a Woke company,' Trump says in Truth Social post - In a post on Truth Social, former President Donald Trump stated in part: "The Bud Light ad was a mistake of epic proportions, and for that a very big price was paid, but Anheuser-Busch is not a Woke company, but I can give you plenty that are, am building a list, and might just release it for the World to see... Anheuser-Busch is a Great American Brand that perhaps deserves a Second Chance? What do you think? Perhaps, instead, we should be going after those companies that are looking to DESTROY AMERICA!" Reference Link

15:07 EST Boeing issues statement on NTSB preliminary report on January 5 investigation - Boeing issued the following statement: "Boeing appreciates the U.S. National Transportation Safety Board's work and will review their findings expeditiously. And we will continue to cooperate fully and transparently with the NTSB and the FAA investigations." Boeing President and CEO Dave Calhoun said, "Whatever final conclusions are reached, Boeing is accountable for what happened. An event like this must not happen on an airplane that leaves our factory. We simply must do better for our customers and their passengers. We are implementing a comprehensive plan to strengthen quality and the confidence of our stakeholders. It will take significant, demonstrated action and transparency at every turn - and that is where we are squarely focused."

14:47 EST NTSB says bolts appeared to be missing from Boeing 737 Max plug door - The National Transportation Safety Board has released its preliminary report on the door plug that blew out midair on Boeing (BA) 737 Max 9 operated by Alaska Airlines (ALK) back on January 5th. According to the document, four key bolts appeared to be missing. Photo evidence released Tuesday seems to show the bolts were missing from the door plug, which had been removed to fix rivets that were damaged in the production process. Reference Link

14:01 EST Pratt & Whitney Canada's PT6A-52 selected to power Piper M700 Fury turboprop - RTX's Pratt & Whitney Canada announced its PT6A-52 engine has been selected by Piper Aircraft Inc. for the Piper M700 Fury aircraft. This is the first time the PT6A-52 engine is used to power a single-engine turboprop. "During our 55-year collaboration with Piper, we've had the privilege of powering some of the most successful single-engine turboprops in the industry," said Anthony Rossi, vice president, Global Sales and Marketing at Pratt & Whitney Canada. "The M700 Fury is an evolutionary addition to the Piper line-up that includes the PT6A-42A-powered M500 and M600 programs. In total, we have supplied Piper with 12 different PT6A engine models, delivering 3,100 engines to power more than 2,000 Piper aircraft."

12:00 EST Coherent rises 16.5% - Coherent is up 16.5%, or $8.14 to $57.56.

12:00 EST Palantir rises 25.9% - Palantir is up 25.9%, or $4.33 to $21.05.

12:00 EST Crown Holdings falls -13.9% - Crown Holdings is down -13.9%, or -$12.31 to $76.02.

11:59 EST WeWork issues statement on recent press reports - WeWork issued the following statement in response to recent press reports: "WeWork is an extraordinary company. As such, we receive expressions of interest from external parties on a regular basis. We and our advisors always review those approaches with a view to acting in the best interests of the company. We continue to believe that the work we are currently doing - addressing our unsustainable rent expenses and restructuring our business - will ensure WeWork is best positioned as an independent, valuable, financially strong and sustainable company long into the future." The statement was issued after The New York Times' DealBook said that WeWork founder Adam Neumann has been trying to buy back the now-bankrupt business with the help of the hedge fund mogul Dan Loeb. Reference Link

11:15 EST Spirit says negotiations with Airbus 'productive'

11:13 EST Spirit AeroSystems fully aligned with Boeing, says CEO Shanahan

11:10 EST NW Natural Water expands presence in Arizona, Oregon with acquisitions - NW Natural Water Company, LLC, a wholly-owned subsidiary of Northwest Natural Holding Company, has expanded further in two states with the acquisitions of Hiland Water Corporation's water utility business in Newberg, Oregon and Truxton Canyon Water Company and Cerbat Water Company near Kingman, Arizona. In addition, NW Natural Water increased its ownership in Avion Water Company, which serves communities in and around Bend, Oregon. "We are excited to see NW Natural Water continue to expand across our existing regions," said Justin Palfreyman, NW Natural Water's president. "We continue to execute on our strategy to build a strong water and wastewater utility business that is focused on safety, reliability, customer service, and environmental stewardship." With these transactions, NW Natural Water serves nearly 175,000 people through approximately 70,000 connections across five states.

10:10 EST TD Synnex appoints Miriam Murphy as president, Europe - TD SYNNEX announced the appointment of Miriam Murphy as the company's new president, Europe. Murphy starts in her new role on April 8th, 2024, and will be responsible for leading the company's 7,000-strong European workforce, driving business strategy and operational execution in the region. She will report to Patrick Zammit, COO, TD SYNNEX - who she succeeds as president, Europe - and she will serve on the company's global executive team. Murphy will lead the distributor's European executive board, which consists of geo leaders, as well as executives responsible for strategic business units and support functions in the region. Murphy returns to TD SYNNEX following two years as chief executive officer, Europe at NTT Ltd.

10:07 EST SEC declares Form S-4 statement effective for WaveDancer, Firefly merger - WaveDancer and Firefly Neuroscience announced that the Registration Statement on Form S-4 relating to the companies' proposed merger was declared effective by the Securities and Exchange Commission. Accordingly, WaveDancer commenced the mailing of a definitive proxy statement to WaveDancer stockholders of record as of the close of business on February 1, 2024. WaveDancer will hold a special meeting of its stockholders to approve the proposed merger on March 14, 2024, at 10:00 a.m. Eastern Time. "We are very pleased that the Registration Statement has been declared effective and are now ready to move forward with our stockholder vote next month. We now expect to close earlier in the second quarter of 2024 than originally anticipated," said Jamie Benoit, Chairman and CEO of WaveDancer. "We hope that bringing Firefly and its FDA-cleared, Brain Network Analytics platform, developed with artificial intelligence, to the Nasdaq will accelerate the company's ability to work with medical professionals to improve outcomes for people suffering from mental illnesses and cognitive disorders and we believe this transaction will translate into greater value for stockholders of both companies."

10:06 EST Verizon, Ericsson complete trial of advanced L4S capabilities - Verizon (VZ) and Ericsson (ERIC) recently completed a trial of advanced Low-Latency, Low-Loss, Scalable Throughput (L4S) capabilities that will optimize Verizon's 5G network for more robust solutions like interactive video, remote control of industrial processes, augmented reality and virtual reality. The L4S trial, conducted in Ericsson's D-15 5G innovation and co-creation lab in Santa Clara, CA, tested an XR application using an XR virtual reality headset over Ericsson's 5G stand alone core connecting to Verizon's C-Band spectrum. The trial demonstrated how enabling L4S signaling in the Radio Access Network allowed content providers to adjust the rates at which they sent their data packets, thereby markedly improving the performance of urgent, high-bandwidth applications over Verizon's 5G network. The results showed latency reduction by up to fifty percent, demonstrating the potential of L4S as a rate adaptation framework for 5G time-critical high data rate applications.

10:04 EST Robinhood Connect integrates with MetaMask for Web3 access - Consensys and Robinhood Markets launched the integration of Robinhood Connect with MetaMask, the world's leading self-custodial web3 wallet. Using MetaMask's Buy Crypto feature, customers can now purchase crypto through Robinhood's low cost order engine. The launch is part of MetaMask's ongoing goal of supporting the adoption of web3 by providing more users with frictionless, secure, and self-custodial onboarding to web3. Self-custodial options like MetaMask allow crypto users to maintain complete control over their digital assets. By integrating two leading platforms in web3 and financial technology, Robinhood's customers can now use Robinhood Connect to purchase crypto through MetaMask's Buy Crypto aggregator, which allows them to seamlessly and easily buy crypto from a number of different providers.

10:01 EST Precipio, Cardinal Health enter distribution agreement for HemeScreen portfolio - Precipio (PRPO) has entered into a distribution agreement with Cardinal Health (CAH) for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio's HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems as well as reference laboratories and physician owned laboratories.

10:00 EST CTS Corporation rises 12.0% - CTS Corporation is up 12.0%, or $4.97 to $46.54.

10:00 EST Palantir rises 25.4% - Palantir is up 25.4%, or $4.24 to $20.96.

10:00 EST Crown Holdings falls -12.6% - Crown Holdings is down -12.6%, or -$11.15 to $77.18.

09:48 EST Helius Medical Technologies Inc trading resumes

09:47 EST Fabrinet falls -18.5% - Fabrinet is down -18.5%, or -$41.34 to $182.26.

09:47 EST Gaotu Techedu rises 8.1% - Gaotu Techedu is up 8.1%, or 32c to $4.25.

09:47 EST Palantir rises 19.4% - Palantir is up 19.4%, or $3.24 to $19.96.

09:43 EST Helius Medical Technologies Inc trading halted, volatility trading pause

09:41 EST Choice Hotels to offer access to Tesla electric vehicle charging stations - Choice Hotels (CHH) announced an agreement with Tesla (TSLA) to offer Tesla Universal Wall Connectors to participating Radisson, Cambria, Comfort, Country Inn & Suites, Quality Inn and other Choice-branded hotels across the U.S. Through this agreement, Choice-branded properties can add four or more charging stations for guests, helping to meet the growing demand for electric vehicle charging and eliminate one of the biggest pain points for EV drivers traveling for business or leisure. Currently, 41% of Choice's Cambria hotels offer EV charging, and by the end of 2024, all are expected to be outfitted with at least one charging station. Cambria guests rank EV charging as one of the top three sustainability priorities that they look for when booking a stay. Additionally, several of Choice's corporate offices currently offer EV charging stations, including North Bethesda, Maryland and Scottsdale, Arizona.

09:38 EST Bit Origin Ltd trading resumes

09:36 EST Phoenix Biotech Acquisition Corp trading resumes

09:33 EST Tenax Therapeutics trading halted, volatility trading pause

09:33 EST FMC Corporation: About 8% of workforce to be impacted by reductions - The company said it has made "strong" progress through a voluntary separation program in the U.S. and has preparations under way for additional workforce reductions company-wide. Approximately 8% of its workforce will be impacted as it consolidates roles and adjusts team structures. Comments taken from Q4 earnings conference call.

09:31 EST Phoenix Biotech Acquisition Corp trading halted, volatility trading pause

09:29 EST Curaleaf acquires Can4Med, terms not disclosed - Curaleaf is pleased to announce its acquisition of Can4Med, a prominent pharmaceutical wholesaler specializing in cannabinoid medications in Poland. This strategic move marks a significant milestone for both companies and underscores Curaleaf's commitment to enhancing patient access to high-quality medical cannabis products across Europe. Poland boasts one of Europe's largest patient populations seeking medical cannabis; by joining forces with Can4Med, Curaleaf International gains a strong foothold in this dynamic market, allowing it to serve patients more effectively and expand its product offerings.

09:23 EST Brera Holdings highlights benefits of a MCO model - Brera Holdings describes some of the benefits of the multi-club ownership, MCO, model. As the only publicly-listed MCO company in the world, holding six assets in its professional sports team portfolio, Brera has already begun to diversify its sports holdings. "We remain on target with our sports team rollup and are now ready to begin the next chapter in expanding the multi-club ownership movement and believe that our unique model, including Nasdaq-listed shares, and rapid international expansion plans, will appeal to fans and savvy investors. As we grow the Brera brand and tournament exposure, we believe that we will benefit from increased industry exposure that these mega deals generate and, whether it's on the pitch or in the board room, Brera is playing to win," stated Pierre Galoppi, Chief Executive Officer of Brera Holdings.

09:21 EST GoPro releases Quik desktop app for macOS - GoPro (GPRO) released an Apple (AAPL) macOS desktop version of its mobile app, Quik. GoPro also announced a new Premium+ $99.99 GoPro subscription tier that offers additional features and benefits beyond the original $49.99 GoPro subscription tier, now known as "Premium." The Quik desktop app is available at no additional charge to GoPro subscribers. It syncs with the Quik mobile app, making it easy to start a project on one device and then finish it on another.

09:18 EST Zenvia signs agreement with stakeholders to address funding gap - Zenvia has entered into agreements with a group of stakeholders aimed at addressing its existing funding gap. These transactions include: agreements with banks for extension of short-term debt, in the total outstanding amount of approximately BRL100M. Payment terms were extended to a total of 36 months, including a 6-month grace period and 30 monthly payments, with final maturity in December 2026; renegotiation of Movidesk's earnout, in the total outstanding amount of approximately BRL 207M - payment terms were extended to a total of 60 months, with final maturity in December 2028; renegotiation of D1's earnout, in the total outstanding amount of approximately BRL20M - payment terms were extended to a total of 36 months, with a 6-month grace period and 30 monthly payments, with final maturity in December 2026; and issuance of 8,860,535 Class A common shares to be acquired by Cassio Bobsin, Zenvia's founder & CEO via Bobsin Corp, for the price of $1.14 per Class A common share, representing a total investment of approximately BRL50M in Zenvia. For a period of 3 years from the closing date of the investment, Bobsin will be entitled to receive additional cash or equity returns on its investment upon the occurrence of certain future liquidity or corporate transaction events.

09:16 EST Zynex receives FDA clearance for next generation NMES device - Zynex announced that it has received clearance from the U.S. FDA for the next generation M-Wave Neuromuscular Electrical Stimulation device. NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals. The M-Wave replaces its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998. The E-Wave was the most powerful and versatile muscle stimulation device on the market for over two decades and the M-Wave builds on that history of performance with a more intuitive design and additional functionality.

09:15 EST Golden Matrix files definitive proxy statement - Golden Matrix Group announced that the Company will hold a Special Meeting of Shareholders to vote on, among other things, the proposed acquisition of the MeridianBet Group. The meeting will take place on March 19, 2024, at 12:00 P.M. Las Vegas time. The meeting will be held in a virtual format, via live audio webcast. Shareholders will be mailed a control number which they will need to join the virtual meeting.

09:14 EST Fortinet announces FortiGate Rugged 70G with 5G Dual Modem - Fortinet announced a new compact, ruggedized appliance explicitly built to deliver enhanced secure networking capabilities and 5G connectivity to operational technology environments. Backed by the latest, fifth-generation Fortinet Security Processing Unit, the FortiGate Rugged 70G with 5G Dual Modem provides unparalleled networking performance, cutting-edge FortiGuard AI-Powered Security Services, and high availability through a 5G dual modem to address a variety of use cases in harsh, remote environments, including full-service remote ATMs within the banking industry.

09:13 EST Rapid7 adds new managed digital risk protection to MDR Service - Rapid7 announced a new Managed Digital Risk Protection, DRP, service for external threat monitoring and remediation that prevents attacks earlier in the threat life cycle. Customers can add this solution to Managed Threat Complete, Rapid7's leading managed detection and response, MDR, service, for extended visibility and response support across their internal and external attack surfaces. "Rapid7 is changing the game in managed security," said Jeremiah Dewey, senior vice president of managed services, Rapid7. "Bringing digital risk protection into Managed Threat Complete gives our experts a broadened view into customers' environments, along with timely, relevant insights. We can therefore proactively uncover the earliest stages of a potential attack and terminate it before it might make an impact."

09:12 EST AMD announces launch of AMD Embedded+ architecture - AMD announced the launch of AMD Embedded+, a new architectural solution that combines AMD Ryzen Embedded processors with Versal adaptive SoCs onto a single integrated board to deliver scalable and power-efficient solutions that accelerate time-to-market for original design manufacturer partners. Validated by AMD, the Embedded+ integrated compute platform helps ODM customers reduce qualification and build times for faster time-to-market without needing to expend additional hardware and R&D resources. ODM integration using Embedded+ architecture enables the use of a common software platform to develop designs with low power, small form factors, and long lifecycles for medical, industrial, and automotive applications.

09:11 EST LPL Financial: Equity Design Group joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Jason Hohenstein, AIF, Kevin Snow, CFP, and William Zoromski of Equity Design Group have joined LPL Financial's broker-dealer, RIA and custodial platforms. The team reported having served approximately $520 million in advisory, brokerage and retirement plan assets, and join LPL from Osaic. Established in Wausau, Wis., the three co-founders have more than nine decades of combined financial services experience between them. They launched Equity Design Group in 1997 with the goal of providing clients with the tailored financial strategies, fiscal education and personal service to help them design their own financial futures.

09:10 EST Mangoceuticals to offer one year supply of Mango ED to Big Game losing team - Mangoceuticals announces that regardless of who loses the Big Game this Sunday, they are prepared to offer a free one-year supply of its Mango ED products for the entire losing team, ensuring they still get sacked after the game. In addition to offering the losing team players the opportunity to score, fans can also get in on the fun with a special discount code equal to the game's point difference, along with discounts site-wide. This code will be available to fans following the results of the Big Game.

09:08 EST AstraZeneca anounces $300M investment in Rockville, MD facility - AstraZeneca is investing $300M in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas. The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics, AbelZeta, Cellectis, and the acquisition of Neogene Therapeutics. Pam Cheng, Executive Vice President of Global Operations & IT and Chief Sustainability Officer, AstraZeneca, said: "We are incredibly excited that more than 150 new highly skilled jobs are being created to bring our scientific work and therapies to clinical trials which could transform the lives of patients around the world. This new $300 million investment will accelerate our ambition to make next-generation cell therapy a reality, ensuring that we are ready to scale and meet the demands of patients."

09:07 EST Syra Health awarded $250K with D.C.'s Department of Behavioral Health - Syra Health has been awarded a one-year contract with the District of Columbia's Department of Behavioral Health worth approximately $250K. The D.C. Department of Behavioral Health provides prevention, intervention, and treatment services and support for children, youth, and adults with mental and/or substance use disorders including emergency psychiatric care and community-based outpatient and residential services. Under the contract, Syra Health will conduct an epidemiological study aimed at identifying the prevalence and types of behavioral health conditions that exist among youth in the district. Once it has completed the study, Syra Health will also provide a detailed report of its outcomes.

09:06 EST Edible Garden announces Pulp sustainable gourmet sauces - Edible Garden AG Incorporated announced that Edible Garden's new line of Pulp sustainable gourmet USDA Organic fermented sauces are now available in all nineteen Woodman's Markets locations across Wisconsin and Illinois. Jim Kras, Chief Executive Officer of Edible Garden, commented, "We are pleased to announce that our Pulp line of sustainable gourmet USDA Organic fermented sauces is now being carried in all nineteen Woodman's Markets locations across Wisconsin and Illinois. Initial feedback received from customers after tasting Pulp has been extremely positive and we remain confident that as more customers experience our sustainable, USDA Organic, 'Bland to Bold' gourmet sauces, they will be eager to try additional items from the product line. Woodman's large retail locations which average 230,000 square feet, are open 24 hours a day, 7 days a week, and carry a wide variety of products, resulting in high traffic volume make them an ideal partner for Edible Garden."

09:05 EST LiqTech expands distribution coverage in UK pool water filtration system market - LiqTech has expanded its distribution with Barr + Wray, a provider of spas, swimming pools, water feature design, engineering and contracting, to include the UK. The expanded agreement builds on two companies' recent partnership in parts of the Middle East to grow LiqTech's Aqua Solution swimming pool water filtration systems in the country.

09:05 EST Zerofox Holdings Inc trading resumes

09:04 EST Kratos welcomes senator, U.S. representative to TDI manufacturing facility - Kratos Defense & Security Solutions recently welcomed U.S. Senator Gary Peters and U.S. Representative Lisa McClain to Technical Directions headquartered in Oxford, Michigan, to showcase Kratos' family of affordable turbine engines and turbogenerators. TDI has developed and refined turbine engine technologies for military applications in Michigan since 1983-providing unique features in support of low-cost, high-production, expendable turbojet engine applications, such as small cruise missiles and other Unmanned Aerial Vehicles. With the engineering, manufacturing, and system integration employees in the Oxford, Michigan facility, TDI's subject matter experts leverage Michigan's deep automotive expertise and apply it to the defense sector and have experience that encompasses all aspects of this turbine engine class, from clean-sheet design, through performance testing, vehicle integration, flight testing, and production manufacturing. By making its own internally funded investments that are not tied to any specific customer or budget process, TDI is able to rapidly develop and be first to market with its engines. Senator Peters, a member of the Senate Armed Services and Appropriations Committees, said, "Michigan defense manufacturers excel at producing innovative solutions to our most pressing national security challenges, and Kratos and the TDI team here in Oxford are a key partner in that success. It was great to see firsthand the important work they are doing to build the next-generation of defense technologies that protect our men and women in uniform, and to celebrate this new contract that will support Michigan-made products and jobs."

09:04 EST GeoVax Labs reports interim data from Phase 2 trial of GEO-CM04S1 - GeoVax Labs announced positive initial safety and immune response findings from its Phase 2 clinical trial at one month following administration of its Covid-19 vaccine, GEO-CM04S1. The trial, evaluating GEO-CM04S1 as a heterologous booster in 63 healthy adults who had previously received the Pfizer or Moderna mRNA vaccine, was fully enrolled at the end of Sept 2023. The study is designed to evaluate the safety and immunogenicity of two GEO-CM04S1 dose levels. The trial remains blinded to dose of vaccine received, with study subjects being followed for a total of one year. To date, there have been no serious adverse events, and adverse events were in line with other routine vaccinations. The immunological responses measured throughout the study period include both neutralizing antibodies against SARS-CoV-2 variants and specific T-cell responses. "We are thrilled by these data and our investigational vaccine designed to protect against severe disease caused by emerging variants of Covid-19," said David Dodd, GeoVax Chairman and CEO. "These interim data reinforce our resolve to bring our expertise in the development of innovative vaccines to address critical public health needs using new approaches and technologies. We look forward to providing further updates regarding the successful progress of the clinical development of GEO-CM04S1."

09:03 EST Invitae trading halted, news dissemination

09:02 EST Triumph Group unit awarded five-year contract with U.S. Army - Triumph Group announced that its Systems, Electronics and Controls business in West Hartford, Connecticut has been awarded a five-year contract with the United States Army to provide an upgrade of the EMC32T Hydraulic Metering Assembly fuel control on the T55 engines, supporting the CH-47 Chinook helicopter fleet. From 2024 through 2028, TRIUMPH will overhaul over 100 EMC32T HMAs per year to the latest configuration. This is the first contract to upgrade the fleet to the newest configuration as part of the U.S. Army's Component Improvement Program. TRIUMPH is uniquely positioned to provide this service as the original designer and manufacturer of the fuel control system.

09:01 EST Getty Images named official photographer of 2024 Fall/Winter NYFW: The Shows - Getty Image has once again been named as the Official Photographer for the 2024 Fall/Winter Season of IMG's New York Fashion Week: The Shows. As the Official Photographer, Getty Images' award-winning entertainment photographers will be delivering high-quality content throughout New York Fashion Week in New York City, all to be distributed exclusively through gettyimages.com. This includes covering all shows at RXR's Starrett-Lehigh building and Fashion Alliance runway shows and presentations, as well as all off-site IMG FOCUS. produced shows, and the first-ever NYFW consumer venue at 21Greene, home to official NYFW programming and merchandise.

08:51 EST AMPED Distribution announces physical distribution of Usher's 'Coming Home' - Alliance Entertainment announced a dynamic start to 2024 for its Independent Music distribution arm, AMPED Distribution, with the launch of the physical release of the highly anticipated album "Coming Home" by pop and R&B sensation USHER on February 9, 2024. "Coming Home" is being released via mega, a music collective founded by L.A. Reid and USHER in partnership with gamma. The album was mainly recorded in Atlanta, GA with many of Atlanta's hottest producers including Sean Garrett, Lil John, The Avila Brothers, Mel & Mus, Tricky Stewart, Rico Love, The-Dream, Jermaine Dupri, and D Mile, among many others. This strategic release ensures availability in brick-and-mortar stores just in time for the Friday street-date, preceding the Super Bowl LVIII halftime show from the mega-star on February 11, 2024.

08:50 EST Cognition Therapeutics identifies key proteins involved in Alzheimer's disease - Cognition Therapeutics announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, that provide new insight into the biology of Alzheimer's disease that is consistent with our understanding of the role the -2 receptor has in regulating Abeta oligomer binding. Using a combination of two high-resolution microscopy techniques: array tomography and Forster resonance energy transfer, Professor Tara Spires-Jones and colleagues at the UK Dementia Research Institute at University of Edinburgh's Centre for Discovery Brain Sciences analyzed protein-protein interactions in over 1 million individual synapses in brain samples from people who had died with Alzheimer's disease. Results detected TMEM97, a protein component of the -2 receptor complex, in close proximity to cellular prion protein on Alzheimer's brain synapses. In addition, results found that Abeta oligomers were proximate to both PrPc, which has been shown to bind Abeta oligomers in neuronal cultures, as well as to TMEM97. These findings support the hypothesis that these receptor proteins may form a complex on the synapse surface with Abeta oligomers binding to one or both proteins.

08:49 EST Phibro Animal Health says Glenn David joins as CFO - Phibro Animal Health (PAHC) announced that Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9 . Mr. Richard Johnson, who is currently serving as Phibro's interim Chief Financial Officer since September 29 will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with his successor...Mr. David brings over 30 years of experience in commercial and financial leadership roles. Mr. David's most recent role was Executive Vice President and Group President, US Operations, Diagnostics, Biodevices and Insurance at Zoetis (ZTS)... Prior to that, he served as Executive Vice President and Group President, International Operations, Aquaculture, Biodevices and Insurance at Zoetis. Mr. David was the Chief Financial Officer at Zoetis from 2016-2021, where he maintained a well-capitalized and financially disciplined business, creating significant value for shareholders and earlier in his career, he served as Senior Vice President of Finance Operations for Zoetis during its Initial Public Offering in 2013. Before the Zoetis IPO, Mr. David served in various financial roles at Pfizer Inc., including Vice President of Global Finance for Pfizer Animal Health and Vice President of Finance for the U.S. Primary Care franchise.

08:47 EST ZeroFox to be acquired by Haveli for $1.14 per share in cash - ZeroFox Holdings entered into a definitive agreement to be acquired by Haveli Investments, a technology-focused private equity firm, in an all-cash transaction with an enterprise value of approximately $350 million. Under the terms of the merger agreement, ZeroFox stockholders will receive $1.14 per share in cash upon completion of the transaction. The per share purchase price represents a premium of 45% over the volume weighted average price for the 90-day period ending February 2, 2024. The transaction, which was unanimously approved and recommended by a Special Committee comprised of independent members of ZeroFox's Board of Directors and unanimously approved by ZeroFox's Board of Directors, is expected to close in the first half of 2024, subject to customary closing conditions, including approval by ZeroFox stockholders and the receipt of required regulatory approvals. The transaction is not subject to a financing condition. Upon completion of the transaction, ZeroFox's common stock will no longer be publicly listed on the Nasdaq Global Market, and ZeroFox will become a privately held company.

08:45 EST Processa Pharmaceuticals regains compliance with Nasdaq minimum bid price rule - Processa Pharmaceuticals has received notice from The Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Market and that the matter is now closed. To regain compliance with the Rule, the Company's ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 2, 2024.

08:45 EST Safe & Green entered into a design build contract with Hostel Cubed - Safe & Green Holdings announced that Safe and Green Holdings has entered into a design-build contract with Hostel Cubed, founded by Jeff Manno and Doug Higgins, to produce their first modular camping cube for the California Coast, the "Coastal Camping Cube." The Company also provided an update that the recently announced $11.3 million purchase order for supplying modular units to a longstanding private infrastructure client is currently on hold. T

08:43 EST Bitdeer announces January 2024 operations update - Bitdeer Technologies Group announced its unaudited mining and operations updates for January 2024. Linghui Kong, Chief Executive Officer of Bitdeer, commented, "During January, we made important progress towards building for the future while delivering solid results in our core business. We mined 330 Bitcoins in total in January, an increase of 123.0% from the same period last year. At the same time, our month-over-month production declined as a result of lower average transaction fees and the curtailments at our Gedu datacenter in Bhutan due to seasonally higher electricity costs, which may continue through the remainder of the first quarter. We are actively exploring strategies to minimize future curtailments and we have already secured fixed-price, carbon-free electricity for the Gedu datacenter from April through the end of the year. In January, we continued our efforts to further diversify and expand our infrastructure. We expect to start land preparation for construction of our 221MW datacenter in Ohio, United States in February. This site will serve as a key component of our ongoing expansion initiatives, and is expected to be completed in 2025. We also continued to advance the construction of our 175MW immersion cooling datacenter at our Tydal mining facility in Norway, which is set to be completed by mid-2025."

08:43 EST Clean Harbors to acquire Hepaco for $400M in cash - Clean Harbors announced it has entered into a definitive agreement with Gryphon Investors to acquire Hepaco, a provider of specialized environmental and emergency response services in the Eastern United States, for $400M in cash. The acquisition is expected to close in the first half of 2024, subject to regulatory approval and other customary closing conditions. Headquartered in Charlotte, North Carolina, Hepaco has more than 2,000 customers, which it services through more than 40 regional locations in 17 states. Its primary offerings include field services, environmental remediation and emergency response services. On an adjusted basis, Hepaco is expected to generate full-year 2023 EBITDA of approximately $36M on $270M of revenues. Clean Harbors expects the acquisition to generate cost synergies of approximately $20M after the first full year of operations, which equates to a post-synergy acquisition multiple of 7.1 times. Clean Harbors expects to fund the acquisition through available cash and the issuance of some additional debt financing.

08:42 EST Tenax announces USPTO grants notice of allowance for patent application - Tenax Therapeutics announced that the United States Patent and Trademark Office, USPTO, has allowed its patent application with claims covering the use of TNX-103, TNX-102, TNX-101, the active metabolites of levosimendan and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients and, titled: "LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION." This new patent, once granted, will provide significant added IP protection through December 2040. The Notice of Allowance indicates that the USPTO plans to grant Tenax expanded IP rights to the use of oral, subcutaneous, and intravenous administration of levosimendan, as well as its active metabolites for the treatment of PH-HFpEF, at all therapeutic doses.

08:40 EST BioSig Technologies' PURE EP platform surpasses 100 patient cases - BioSig Technologies announced that physicians have completed over 100 cases with the Near Field Tracking algorithm, an innovative and proprietary feature recently launched on the Company's PURE EP Platform. "BioSig's PURE EP Platform and its new algorithms are pioneering the way in the automatic interpretation of cardiac cellular reaction to catheter energy delivered," commented Hicham El Masry, MD, FHRS, Cardiac Electrophysiologist at Mayo Clinic Arizona. "NFT is a unique algorithm for assessing lesion efficiency and increases my procedural efficiency and confidence when it comes to distinguishing between healthy and scar or ablated tissue. This revolutionary feature has become a critical tool during all my complex cases."

08:40 EST Zerofox Holdings Inc trading halted, news pending

08:39 EST African Agriculture appoints Rhodes as CEO - African Agriculture announced the hiring of Michael Rhodes as the company's Chief Executive Officer. Rhodes brings decades of operating experience in large-scale agriculture across Africa, including hands-on management of over 16,000 hectares of productive farmland across more than eight East and West African nations. Rhodes succeeds Alan Kessler as Chief Executive Officer, who successfully grew and transitioned African Agriculture from a private company through its NASDAQ listing. Kessler will continue in his role as Chairman of the African Agriculture board and continue in the operational role of Chief Strategy Officer.

08:38 EST Siyata Mobile expands alliance with Hyperion Partners - Siyata Mobil has expanded its alliance with Hyperion Partners to include distribution of the Company's mission critical PoC SD7 handsets and accessories.

08:36 EST Check Point: CEO search could take 6 months-2 years

08:35 EST SP Plus implements parking management innovations at Miami Valley Hospital - SP+ Corporation is now operating and managing five parking facilities with its Sphere technology platform at Miami Valley Hospital, in Dayton, Ohio. The implementation of Sphere Commerce Digital Ticket technology for Miami Valley Hospital features gated entry and exits, along with a completely digital experience - including QR code capability, and a digital ticket, eliminating the need for paper tickets. In addition, Sphere License Plate Recognition makes access to the hospital as simple as driving-in. Additionally, if individuals are planning to be at the hospital for multiple days, an added convenience is the ability to make a parking reservation in advance to save time.

08:34 EST Veru announces FDA clearance of IND application for Phase 2b with enobosarm - Veru announced that the U.S. Food and Drug Administration, FDA, has cleared the company's Investigational New Drug, IND, application for its Phase 2b clinical study to evaluate enobosarm, an oral novel selective androgen receptor modulator, SARM, to preserve muscle mass and physical function and further increase fat loss in patients receiving a Glucagon-like peptide-1 receptor agonist drug for potentially higher quality weight loss. The Phase 2b, multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial is designed to evaluate the safety and efficacy of enobosarm 3mg, enobosarm 6mg, or placebo as a treatment to augment fat loss and to prevent muscle loss in 90 sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness. The primary endpoint is lean body mass, and the key secondary endpoint is total body fat mass at 16 weeks. The clinical study is expected to begin by April 2024 with the topline clinical results from the trial expected in the end of the fourth calendar quarter of 2024.

08:33 EST Adeia demonstrates hybrid bonding technology during Chiplet Summit - Adeia announced that it is showcasing its hybrid bonding technology at the Chiplet Summit on February 6 through 8, 2024, at the Santa Clara Convention Center.

08:32 EST Sellas Life Sciences announces publication of preclinical data on SLS009 - SELLAS Life Sciences Group announced a publication in Oncotarget revealing the underlying mechanisms of action behind the anti-proliferative effects of SLS009, its potent, highly selective CDK9 small molecule inhibitor, in various hematologic malignancies. The publication is entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies". The research provides a robust pharmacodynamic and mechanistic foundation for the antiproliferative effects of SLS009 in hematologic cancers. SLS009 has exhibited significant anti-tumor activity in various human hematological malignancies in early-stage clinical trials and has demonstrated its potential in tumor growth inhibition with a dose-dependent induction of apoptosis. The research shows that through rapid CKD9 inhibition, SLS009 depletes the protective anti-apoptotic proteins produced downstream of CKD9. The Company believes that this induced cancerous cell apoptosis is a key mechanism behind SLS009's robust anti-cancer activity. "The study establishes CKD9 as a targetable vulnerability in various human hematological malignancies highlighting the potential for SLS009 superior kinome selectivity compared to other inhibitors," said Dragan Cicic, MD, Senior Vice President, Chief Development Officer, of SELLAS. "These findings provide a strong rationale for ongoing clinical trials and underscore SLS009's potential as a highly selective and effective treatment for hematological malignancies. We are encouraged by the ongoing clinical progress of SLS009 and excited to see how the preclinical data seamlessly translates into clinical settings. We look forward to reporting topline data from our Phase 2a clinical trial of SLS009 in relapsed and/or refractory acute myeloid leukemia patients this quarter and next, and topline data from the Phase 1b/2 study of SLS009 in peripheral t-cell lymphomas by the end of the second quarter."

08:31 EST CLS Holdings' City Trees reports record-breaking sales month - The company said, "In the bustling heart of the production facility at City Trees, they recently celebrated an extraordinary milestone as they achieved their most successful sales month to date. This accomplishment is especially noteworthy considering the persistent challenges that the cannabis industry faces. Navigating through regulatory complexities, shifting public perceptions, and market fluctuations, the team at City Trees has displayed resilience, creativity and dedication, solidifying their position as a trailblazer in the cannabis market. City Trees commitment to quality and innovation has propelled them to the forefront of the industry, making City Trees the number one vape and concentrate brand in Nevada, according to BDSA Analytics. As they continue to set sales and production records, they remain the standard of excellence in cannabis production, providing consumers with a diverse range of premium cannabis products that continue to redefine industry standards. The recent achievement of their most successful sales month underscores the brand's strength and solidifies their position as the industry leader, poised for continued growth in the dynamic world of cannabis. January '24 witnessed a notable reduction in overall inventory, decreasing to $1.5 million from $2.89 million in January '23. This inventory decrease evidences an enhanced operational efficiency and a capacity to maintain a lean structure without compromising robust sales outcomes. The brand's remarkable success is further underscored by its strategic expansion into New Mexico. This pivotal move has not only broadened its geographical reach but has also significantly supported its overall achievements. The recent milestone includes the successful production and dispatch of the brand's inaugural 10,000 units in New Mexico-a testament to the great planning and execution of its expansion strategy."

08:29 EST Sacks Parente Golf's Newton Shafts expands into Club Champion stores - Sacks Parente Golf announces the mid-February availability of golf shafts from its Newton Shafts division -- starting with the Newton Motion driver shaft -- in all 126 Club Champion stores nationwide. "We are thrilled to announce that our first Newton Shafts offering, the Newton Motion premium shafts, will soon be available at all Club Champion stores nationwide," said Greg Campbell, Executive Chairman, Sacks Parente Golf. "The Newton Shaft provides unprecedented performance for all levels of golfers from the pro to the weekend warrior. We are confident that Club Champion customers will be thrilled with these shafts and are looking forward to our continued relationship with this retailer."

08:28 EST Allegro MicroSystems introduces high-bandwidth current sensor technologies - Allegro MicroSystems announced the launch of its new high-bandwidth current sensors, the ACS37030 and the ACS37032, which enable high-performance power conversion with GaN and SiC technologies in electrified vehicles, clean energy solutions and data center applications. Current high-power-density GaN and SiC FET charging and power infrastructures demand high-speed, low-loss devices to ensure efficiency and reliability. Existing current-sensing solutions have limited operating ranges, as well as added size and weight that result in designs with additional components and larger bills of materials. To address these challenges, Allegro has introduced two high-bandwidth current sensors - the ACS37030 and ACS37032 - designed to provide efficiency and high-performance with reduced design time and board space. They employ a dual signal paths approach, with one path capturing low-frequency and DC current using Hall-effect elements and the other path capturing high-frequency current data through an inductive coil.

08:27 EST Blink Charging, Allegiant Stadium team to provide on-site EV charging - Blink Charging announced it has been named as the official EV charging provider for Allegiant Stadium, home of the Las Vegas Raiders, providing much-needed reliable EV charging solutions for drivers. As demand and popularity for electric vehicles surge, the installation of Blink's chargers across Allegiant Stadium stands poised to empower both fans and employees, offering them the convenience of charging their EVs. These chargers, operational 24/7, will provide EV owners with the flexibility to utilize Allegiant Stadium's charging facilities at any time. "Allegiant Stadium and the Las Vegas Raiders are at the forefront of sustainability, and we're proud to be chosen as the official charging provider for the stadium," said Mike Battaglia, Chief Operations Officer at Blink Charging. "Through this collaboration, Blink's leading EV infrastructure will now be relied upon by those attending some of the biggest sporting and entertainment events in the world, advancing the shift to electrification."

08:25 EST Aveo Pharmaceuticals announces publication of data from Phase 3 TIVO-trial - AVEO Oncology announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA in patients with relapsed or refractory, R/R, advanced renal cell carcinoma, RCC. In the publication, FOTIVDA demonstrated a consistent safety profile and a long-term survival benefit in patients who were alive and progression-free at 12 months, suggesting a durable clinical benefit and safety across age groups regardless of prior treatment. TIVO-3 compared the efficacy and safety of the vascular endothelial growth factor receptor tyrosine kinase inhibitors FOTIVDA and sorafenib in patients with R/R advanced RCC whose disease progressed with two or three prior systemic therapies. The trial included a predefined subgroup of patients who were previously treated with both an immuno-oncology therapy and a VEGFR TKI. The post hoc analysis showed investigator-assessed landmark long-term progression-free survival rates were higher with FOTIVDA compared to sorafenib. After 22.8 months mean follow-up, the overall survival hazard ratio for FOTIVDA was 0.89; when conditioned on a clinically meaningful 12-month PFS time point, FOTIVDA showed significant improvement in OS compared to sorafenib. Mean time on treatment was 11.0 months with FOTIVDA and 6.3 months with sorafenib. There were fewer treatment-related adverse events and lower dose modification rates with FOTIVDA than with sorafenib as well as fewer grade greater than or equal to3 TRAEs on FOTIVDA than sorafenib. Dose modification rates were lower with FOTIVDA than with sorafenib across age and prior IO subgroups; and prior IO therapy did not impact dose reductions or discontinuations in either arm.

08:23 EST Aprea Therapeutics announces IND application for APR-1051 - Aprea Therapeutics announced that it has submitted an Investigational New Drug, IND, application to the U.S. Food & Drug Administration, FDA, to initiate clinical trials of APR-1051. APR-1051 is an oral inhibitor of WEE1 kinase, which plays important role in cell cycle regulation and DNA damage repair. Based on preclinical studies, we believe APR-1051 is potentially differentiated from other WEE1 inhibitors in its: molecular structure; selectivity for WEE1 versus off-target inhibition of the polo-like kinase, or PLK, family of kinases; and potentially superior pharmacokinetic properties. Aprea has conducted extensive pre-clinical studies with APR-1051, which have demonstrated that the molecule may have highly potent anti-tumor activity, with a potentially favorable pharmacokinetic profile. "Submission of an IND represents an important milestone for our APR-1051 development program," said Dr. Oren Gilad, President and CEO of Aprea. "APR-1051 is a next generation inhibitor of WEE1 kinase and, based on its unique characteristics, we believe it will be best in class. Pending clearance of the IND by FDA, we plan to commence clinical testing in the first half of 2024."

08:22 EST AGF Management announces normal course issuer bid - AGF Management Limited announced that the Toronto Stock Exchange has approved AGF's notice of intention to renew its normal course issuer bid in respect of its Class B Non-Voting Share As at January 26, 2024, there were 64,360,7481 Class B Non-Voting Shares issued and outstanding and the public float consisted of 47,352,690 Class B Non-Voting Shares. Under the announced normal course issuer bid, AGF is permitted to purchase up to 4,735,269 Class B Non-Voting Shares, representing approximately 10% of the public float for such shares as of January 26, 2024. Purchases under the normal course issuer bid may commence on February 8, 2024 and continue until February 7, 2025, when the bid expires. Pursuant to the Articles of AGF, the Class B Non-Voting Shares may not be purchased by AGF at a price which exceeds more than 15% of the weighted average price at which the Class B Shares traded on the TSX during the ten trading days immediately preceding the date of any such purchase. AGF announced that it will be entering into an automatic purchase plan with a broker during the normal course issuer bid. The Plan is effective as of February 8, 2024 and should terminate together with the normal course issuer bid. The Plan allows for purchases by AGF of its Class B Non-Voting Shares, subject to certain parameters.

08:21 EST Sensus Healthcare collaborates with CureRays - Sensus Healthcare announces a new multi-faceted collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, Calif. Under the collaboration, CureRays will provide Sensus' dermatology customers with oversight and supervision to assure patient safety, quality, reliability of outcomes and conformance with regulatory requirements, in particular in states where regulations covering the use of ionizing radiation have been tightened. In addition, CureRays will research new indications for Sensus' superficial radiotherapy, including inflammatory diseases. "This collaboration is the culmination of several years of discussion that started early in the COVID-19 pandemic, when we learned that Drs. Khan and Hess were treating COVID pneumonia with low-dose radiotherapy for infectious and inflammatory diseases. We were anxious to help stem fatalities in any way we could, and we've been impressed with their commitment to patient care. CureRays is well-versed in our SRT-100 Vision system, which they are utilizing to treat skin cancer and keloids," commented Joe Sardano, chairman and chief executive officer of Sensus.

08:19 EST Twist Bioscience and Element Biosciences team on Exome sequencing solutions - Twist Bioscience and Element Biosciences announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element's AVITI System. "Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally. Pairing Twist's robust NGS workflows with Element's AVITI technology will offer customers an economical and streamlined approach to next generation sequencing," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Because our tools are sequencer agnostic, we can extend the reach of our products with innovative companies like Element, and continue our commitment to empowering researchers to accelerate breakthroughs in scientific discovery by providing advanced tools." "We've laid out an ambitious product roadmap for 2024 to redefine what is possible on a sequencer and make it even easier for labs to produce the highest quality data at a low cost," said Molly He, Ph.D., CEO and co-founder of Element Biosciences. "With the Twist for Element Exome Workflow, we are able to provide our customers with easy access to Twist's Exome 2.0 panel and high performing library preparation and target enrichment reagents, saving them potential downstream sequencing costs by reducing per sample sequencing requirements." The Twist for Element Exome Workflow is a purpose-built solution for Element's AVITI chemistry, alleviating the need for additional workflow steps for linear library conversion. The workflow will include Twist's library preparation and target enrichment bundled with the Exome 2.0 and comprehensive spike-in. The Exome 2.0 delivers best-in-class sequencing due to its high uniformity and low off-target rate. It is designed to detect rare and inherited diseases, as well as germline cancers...

08:18 EST Ohmyhome partners with SG Alliance to extend home-related insurance - Ohmyhome announced its strategic partnership with SG Alliance. This partnership aims to provide access to comprehensive insurance solutions tailored to the needs of homeowners and homebuyers, and also bring Ohmyhome's suite of services to SG Alliance's clients. As Ohmyhome's preferred partner, SG Alliance is able to represent more than 30 insurance partners to provide different quotations for clients to compare. So customers can save the hassle in comparing and choose the most affordable plan to protect their home. Homeowners and homebuyers of Ohmyhome will also enjoy exclusive benefits as a result of the partnership.

08:17 EST Reviva Pharmaceuticals to host KOL event to discuss data on brilaroxazine - Reviva Pharmaceuticals announced that it will host a key opinion leader, KOL, event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP and Mark Opler, PhD, MPH, who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine, a next-generation serotonin/dopamine modulator, as a potential treatment. To register, click here.

08:16 EST A-Mark Precious Metals to acquire LPM Group for upfront consideration of $41.5M - A-Mark Precious Metals has entered into a non-binding letter of intent with AMS Holding providing for three transactions, including the proposed acquisition of LPM Group Limited, one of Asia's largest precious metals dealers. The proposed transactions are subject to the preparation and execution of definitive agreements and are expected to close simultaneously in February 2024, subject to the receipt of customary closing conditions and required third party consents or approvals, including the consent of the lenders under A-Mark's Trading Credit Facility. Established in 2012, LPM is one of the largest precious metals wholesalers in Asia. Headquartered at the heart of Hong Kong's Central Financial District, LPM boasts the city's largest numismatics showroom. LPM offers a wide selection of products through its retail store and 24/7 online trading platform, including recently released silver coins, gold bullion, certified coins, and the latest collectible numismatic issues. The company's global customer base spans sovereign and private mints, manufacturers and fabricators, investors, collectors, e-commerce customers, and other retail customers. The letter of intent provides that A-Mark will acquire 100% of the issued and outstanding equity interests of LPM Group Limited from AMS for total upfront consideration of $41.5 million, consisting of $37.5 million in cash, subject to certain closing adjustments, and $4.0 million of A-Mark common stock. The letter of intent further provides that LPM will have a tangible net worth of $11.5 million inclusive of net cash and precious metals inventories. The letter of intent also contemplates that AMS will have the potential to earn up to an additional $37.5 million in cash based on achievement of certain Earnings before Interest, Taxes, Depreciation, and Amortization targets for 2024, 2025 and 2026. Under the letter of intent, A-Mark affiliate, Pinehurst Coin Exchange, one of the nation's largest distributors of modern certified coins of which A-Mark owns 49.0%, will acquire all the assets of ModernCoinMart from AMS for $5.5 million, subject to certain closing adjustments. MCM is one of the fastest growing dealers in the U.S. and ships to many international destinations. As part of the asset purchase, Pinehurst will acquire $3.0 million of inventory, along with MCM's customer list, brand name, and related intellectual property. The letter of intent further provides that a proposed joint venture consisting of A-Mark, Pinehurst and Stack's Bowers Numismatics, LLC, an affiliate of A-Mark, will acquire a common equity interest in AMS equivalent to 10% of the total, fully diluted common equity interests in AMS. As part of the proposed investment, A-Mark CEO Greg Roberts will join the AMS board of directors.

08:15 EST Iridex receives European patent on MicroPulse technology - Iridex Corporation announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use". This groundbreaking patent further protects Iridex's intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse devices that utilize the patented technology. Revolutionizing Eye Care with Precision and Safety The patented technology delivers a laser system capability for delivering short, controlled-width pulse trains. This technology is designed to minimize the risk of full-thickness retinal damage and vision loss, a common concern with traditional laser treatments with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications and beyond.

08:13 EST Plug Power drops 3% to $4.20 after downgrades at Seaport , UBS

08:12 EST Gain Therapeutics announces preclinical data on GT-02287 - Gain Therapeutics announces preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson's disease models following delayed administration. The data was accepted as a late-breaker abstract and will be presented at the 20th Annual WORLDSymposium being held in San Diego this week. "We believe the data showing complete restoration of motor function in a therapeutic model are remarkable and further support the potential of GT-02287 to slow or stop the progression of Parkinson's disease, a disease for which only symptomatic treatments are available to patients at this time," said Matthias Alder, Gain Therapeutics' Chief Executive Officer. "We are currently conducting a Phase 1 clinical trial of GT-02287 in healthy adults to evaluate its safety, tolerability, and pharmacokinetics, and plan to commence treatment of patients in an extension of that clinical trial in Q3 of this year."

08:11 EST electroCore issued U.S. patent related to systems, methods for treating diseases - electroCore announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family, U.S. Patent No. 11,894,148 entitled "Systems and Methods for Treating Patients With Diseases Associated With Viruses" generally relates to methods for treating disorders with viruses in the COVID family using electrical impulses transcutaneously to the vagus nerve for about 30 seconds to about 5 minutes, from 2 to 5 times per day, to reduce a level of C-reactive protein in the blood of the patient.

08:10 EST Ultragenyx announces data demonstrating treatment with UX111 - Ultragenyx Pharmaceutical announced data demonstrating treatment with UX111 AAV gene therapy resulted in rapid and sustained decreased levels of heparan sulfate in cerebrospinal fluid in patients with Sanfilippo syndrome type A, and that sustained reduction in CSF HS exposure over time was correlated with improved long-term cognitive development. These data are from the modified intention to treat group in the pivotal Transpher A study. Following treatment with UX111, levels of CSF-HS decreased within the first month post treatment in all patients. 8 of 17 patients in the mITT group who reached 24 months post-treatment achieved an overall mean percent reduction from baseline of 51%. An alternative way to assess CSF-HS is to look at the reduction in CSF HS exposure over time post-administration of UX111 using time-normalized area under curve. The 17 patients in the mITT group had a mean follow-up duration of 29 months. There was a mean reduction in CSF HS exposure of 63% using time-normalized AUC. Cognitive function was measured using Bayley-III cognitive raw scores and an estimated yearly rate of change was calculated to reflect a patient-specific rate of change in BSITD-III cognitive raw scores after UX111 treatment. At the time of the data cut-off, the individual EYC in cognitive raw scores showed a positive rate of change indicating either stability or gains from baseline in 16 of the 17 patients during the expected window of plateau into decline, defined as greater than30 months of age.

08:09 EST Flywire partners with State Bank of India to digitize education payments - Flywire has partnered with State Bank of India to enable Indian payers to seamlessly and digitally pay international education-related fees in their local currency to higher education institutions all over the world. The integration provides students and families a streamlined and completely digital experience when making high-value education payments, and helps them comply with the Liberalized Remittance Scheme, which are guidelines to help streamline overseas transactions and investments for residents of India. Flywire integrates directly into SBI's banking platform, providing Indian students with a fully digital checkout experience for their transactions, ranging from application fees to tuition payments. The solution is available only to local currency account holders of SBI in India. Students can make the payment in three simple steps from within their SBI net banking platform, all in Indian rupees, and can track the payment through to when the funds are delivered to their university. Likewise, institutions accepting payments through Flywire benefit from receiving payments on time in the local currency, as well as full transparency into the transaction history, which eases their reconciliation processes and streamlines operational efficiencies.

08:08 EST Seer announces publication of study on Proteograph workflow - Seer announced a publication in Nature Communications from a study led by Weill Cornell Medicine showing Seer's Proteograph workflow to potentially unveil novel proteogenomic insights into genetics-based drug and biomarker discovery for precision medicines. Designed to address the challenges with affinity-based proteomic approaches for protein quantitative trait loci studies, the scalable, high-resolution Proteograph workflow enables scientists to link genetic variation with protein abundance with peptide level resolution. In the paper, the researchers used Seer's first-generation Proteograph Assay workflow upstream of mass spectrometry to quantify over 18,000 peptides from approximately 3,000 proteins in more than 320 blood samples to detect and quantify blood-circulating proteins in the presence of protein-altering variants, PAVs. The study found 184 PAVs in 137 genes, confirmed by their variant peptides in mass spectrometry data, known as MS-PAV. Most MS-PAVs were aligned with known genetic markers, validating the target specificity of the method. Some MS-PAVs overlapped with trans-pQTLs, shedding light on potential causal proteins. Lastly, the study revealed proteins overlooked by traditional methods, like the incretin pro-peptide linked to type 2 diabetes and cardiovascular disease.

08:07 EST Aspira Women's Health announces OvaSuite distribution agreement in Philippines - Aspira Women's Health announced the signing of a 5-year distribution agreement granting Hi-Precision Laboratories the exclusive right to market and distribute the OvaSuite portfolio in the Philippines. The commercialization of OvaSuite products in the Philippines will commence upon receiving approval from the local regulatory authority. In consideration of the licenses and rights granted by Aspira, Hi-Precision Laboratories will pay royalties to Aspira for each test performed in the Philippines. "We are thrilled to partner with one of the largest medical laboratories in the Philippines, an important step towards achieving our goal to make OvaSuite available worldwide," said Nicole Sandford, President and Chief Executive Officer of Aspira. "Moreover, the Clinical Performance of a Multivariate Index Assay in Detecting Early-Stage Ovarian Cancer in Filipino Women study clearly demonstrated improvements in the detection of early-stage ovarian cancers when an Aspira test was incorporated in the clinical assessment of women presenting with an ovarian mass."

08:06 EST NightHawk Biosciences completes name change to Scorpius Holdings - NightHawk Biosciences had completed its name change from NightHawk Biosciences, Inc. to Scorpius Holdings, Inc., to better reflect the Company's successful shift into a pure-play, large molecule biomanufacturing CDMO. In connection with the name change, the Company's ticker will change to "SCPX" effective today, February 6, 2024. The name and symbol changes do not affect the Company's share structure or the rights of the Company's shareholders, and no further action will be required by existing shareholders.

08:06 EST DocuSign announces restructuring plan, to reduce workforce by 6% - DocuSign announced a restructuring plan designed to strengthen and support the company's financial and operational efficiency while continuing to invest in product and related initiatives that will provide the foundation to realize its multi-year growth aspirations as an independent public company. DocuSign also announced that it expects to meet or exceed the company's Q4 and FY 2024 financial guidance as described in the earnings release on December 7, 2023. As part of the Restructuring Plan, the company expects it will restructure and reduce its current workforce by approximately 6%, with the majority of impacted positions in the company's Sales & Marketing organizations. The Company currently estimates that it will incur approximately $28 to $32 million in non-recurring restructuring charges in connection with the Restructuring Plan, consisting primarily of cash expenditures for employee transition, notice period and severance payments, employee benefits, and related costs as well as non-cash expenses related to vesting of share-based awards. The company expects that the majority of the restructuring charges will be incurred in the first quarter of fiscal 2025, and that the execution of the Restructuring Plan will be substantially complete by the end of the second quarter of fiscal 2025.

08:04 EST Lipocine confirms dosing regimen for pivotal study of LPCN 1154 - Lipocine announced that results from a multi-dose clinical study have confirmed the LPCN 1154 48-hour dosing regimen for the upcoming NDA enabling pivotal pharmacokinetic study. LPCN 1154 is an oral neurosteroid being developed by Lipocine for the treatment of postpartum depression. Lipocine has previously confirmed with the FDA acceptance of a proposal for a 505(b) NDA filing based on a single pivotal study comparing exposure of LPCN 1154 with the approved IV infusion of brexanolone. Following a successful meeting with the FDA, Lipocine reached agreement on the use of exposure parameters and criteria to assess comparable exposure to IV infusion brexanolone. Consistent with the goal of NDA submission by the end of Q4, the company anticipates top line results late in Q2 from the crossover pivotal study of LPCN 1154 with the reference product IV brexanolone.

08:03 EST MasterCard partners with NovoPayment to grow Mexico footprint - NovoPayment announced that it has received Mastercard certification, as part of the Mastercard Network Enablement Partner program, to switch and process Mastercard transactions in Mexico. The Network Enablement Partner program is a Mastercard initiative that enables Service Providers - the vendors of Mastercard-Licensed Issuers and Acquirers who typically have a fully indirect relationship with Mastercard - to play a pivotal role in expediting product innovation, reducing time to market and enhancing overall performance and operational efficiency for their customers. The direct partnership with Mastercard opens the door for Service Providers to collaborate on initiatives that drive value, innovation and seamless experiences in the evolving payment ecosystem. Prior to Mexico, NovoPayment has received certifications in Chile, Colombia, Ecuador, Peru and Venezuela as card issuer processors.

08:02 EST MoneyLion partners with EY in digital transformation services for banks - MoneyLion is partnering with Ernst & Young - EY US -, to help drive innovation and growth within the banking sector. The alliance leverages MoneyLion's embedded finance platform to help enhance the technological capabilities of traditional banking institutions. With MoneyLion's embedded marketplace infrastructure and technology, data insights and content solutions combined with EY US teams' existing core-banking modernization offerings and Nexus for Banking Platform, the Alliance is designed to provide a comprehensive suite of FinTech solutions to help scale acquisition strategies and service models as well as foster organic growth and engagement within financial institutions' customer base.

07:39 EST Knight Therapeutics announces launch of Bijuva in Canada - Knight Therapeutics announced the launch of BIJUVA capsules in Canada. BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus. VMS affects 60% to 80% of women entering menopause and are commonly known as hot flashes or flushes and night sweats. BIJUVA is a once-daily combination of bioidentical estradiol and progesterone in a single oral capsule. The two hormones included in BIJUVA have the same structure as the hormones produced and circulating in a woman's body.

07:38 EST Hyzon Motors and New Way Trucks to co-develop fuel cell-powered refuse vehicle - Hyzon Motors and privately held New Way Trucks announced a Joint Development Agreement to develop a fuel cell powered refuse vehicle for the North American market. Hyzon and New Way plan to start the advanced phases of truck development, with the initial base FCEV prototype ready for refuse collection equipment integration. Hyzon will be responsible for the supply and integration of its advanced fuel cell technology and integrated powertrain, while New Way will be responsible for the supply and integration of the prototype's Sidewinder XTR automated side-load refuse body. Initial customer trials for the parties' first North American prototype truck are planned to begin in the first half of 2024 with a mix of public and private refuse fleets. Additionally, Hyzon is targeting initial commercial vehicle deliveries in 2025 on the back of potential successful trials.

07:38 EST Vivos Therapeutics highlights favorable market developments - Vivos Therapeutics highlighted certain significant favorable market developments creating new opportunities to widen its funnel of potential users of Vivos' oral appliance therapies. On November 2, 2023, the U.S. Food and Drug Administration granted, for the first time ever, a 510(k) clearance to the Vivos CARE appliances to treat moderate and severe OSA in adults. Considering the very recent discontinuation of many devices by Philips Respironics, there will most likely be a ripple in the supply chain which ultimately will affect patient care. Vivos has demonstrated and proven to the FDA safety and efficacy for its CARE devices to treat severe OSA, and it is well positioned to assist patients and providers that have been or could be impacted by these latest industry developments. Kirk Huntsman, Chairman and CEO of Vivos, stated "We believe that CPAP recalls leaving millions of OSA sufferers looking for alternatives, together with United Healthcare's recognition of oral appliance therapy as a prerequisite for surgical treatment in adult patients with moderate to severe OSA, create a significant opportunity for us to widen the funnel of potential users of our appliances. For the first time ever, adult patients with moderate to severe OSA now have a safe and highly effective alternative treatment option to CPAP through our CARE appliances, a treatment that has been proven to significantly improve and even clinically resolve OSA symptoms, over a limited treatment time."

07:35 EST Agrify announces successful installation of a PX-30 System at Michigan facility - Agrify Corporation announced the successful installation of a PX-30 Hydrocarbon Extraction System at its customer's Michigan facility. "We are thrilled to announce the successful installation of another PX-30 hydrocarbon extraction system at one of our valued customers here in the state of Michigan," said Brian Towns, EVP & General Manager at Agrify. "This state-of-the-art technology aligns with our mission to provide our clients with the best tools for long-term success in an evolving industry. Agrify is committed to all of our customer's success as their success is our success."

07:36 EST Wayfair says Decorify App now available on Apple Vision Pro - Wayfair (W) announced Decorify, Wayfair's generative AI pilot application, is now available on Apple Vision Pro (AAPL). Using the app, users can quickly and easily redesign their spaces in familiar and new styles, and experience their new spaces in an immersive environment. The Wayfair Decorify app is currently available in the visionOS App Store for Apple Vision Pro.

07:34 EST nCino announces Mechanics and Farmers bank live on nCino Platform - nCino announced that Mechanics and Farmers Bank is live on the nCino Cloud Banking Platform. The technology upgrade is helping M&F process loans more quickly and creating increased convenience and connectivity for the underserved markets it intentionally serves. "The partnership we have with M&F Bank is foundational to the transformation the Bank is driving within their operations," said Will Cameron, SVP of U.S. Financial Institutions at nCino. "We are proud to provide M&F with the technology platform they need to provide faster and easier access to capital for the communities they serve while strengthening its own performance and becoming more efficient."

07:33 EST BridgeBio reports inducement grants under Nasdaq listing rule - BridgeBio Pharma announced that on February 05, 2024, the compensation committee of BridgeBio's board of directors granted thirty-five new employees restricted stock units for an aggregate of 123,838 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on February 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

07:31 EST Spirit AeroSystems not providing FY24 guidance - The company stated, "Spirit will not be providing guidance at this time until there is further clarity on the timing of 737 MAX production rate increases from our customer in relation to FAA approval and ongoing price negotiations with Airbus."

07:27 EST Tellurian explores opportunities in sale of Haynesville upstream assets - Tellurian announced it has asked its financial advisor, Lazard, to explore opportunities for the sale of Tellurian's upstream business. Chief Executive Officer Octavio Simoes said, "As we commercialize Driftwood LNG, Tellurian has been reviewing its strategy, including the dynamics of the U.S. natural gas market in the context of global LNG demand. We have concluded that there are alternative gas supply strategies available to us from various basins and our ownership of upstream assets is not necessary at this stage of Tellurian's development. We have a substantial number of drilling locations that we believe will be highly attractive to oil and gas producers that can develop them more quickly than we would."...Chief Executive Officer Octavio Simoes said, "As we commercialize Driftwood LNG, Tellurian has been reviewing its strategy, including the dynamics of the U.S. natural gas market in the context of global LNG demand. We have concluded that there are alternative gas supply strategies available to us from various basins and our ownership of upstream assets is not necessary at this stage of Tellurian's development. We have a substantial number of drilling locations that we believe will be highly attractive to oil and gas producers that can develop them more quickly than we would."

07:23 EST Magnolia Oil & Gas increases board size - Magnolia Oil & Gas announced that its board of directors has increased the size of the board from seven to eight directors and has appointed David Khani as an independent director of the board, effective immediately. Khani will serve as a member of the Audit Committee.

07:21 EST CMC Metals acquires Amy, Silverknife properties, additional Mineral Tenure - CMC Metals has completed the final payment on the Silverknife and Amy Properties and also acquired an additional Mineral Tenure at Amy. The deal was completed on February 1, 2024 with the Optionor, Mr. Steven Scott a businessman and prospector. As a result, CMC is now a 100% owner of the aforementioned Properties as of the effective date of the Agreement. The original final payment of the option agreement was amended and subsequently a payment of 2,000,000 common shares, subject to a four month hold period from the effective date, was provided to Mr. Scott as the final payment. The Silverknife Property is located immediately west of Coeur Mining Inc. very high-grade silver-lead-zinc-critical minerals carbonate replacement deposit located in the emerging Rancheria Silver District in north-central British Columbia. CMC has only conducted preliminary exploration at the Silverknife Property and intends to focus future exploration efforts on the North Tootsee area of the Property. North Tootsee is underlain by limestones assigned to the McDame unit which are the host rock to the Silvertip mine located less than 2 kilometers to the east. CRD style deposits typically form in clusters, along structural corridors, and adjacent to intrusives such as granites/granodiorites which provide the heat source for the movement of mineralized fluids into overlying sediments such as limestones. Tootsee North is areally larger in size than the current footprint of the Silvertip mine, is located proximal to the heat source proven by CMC's small 2023 drilling program, and McDame is locally noted to be mineralized in showings just north of Silverknife. Future exploration efforts will include completion of road access to the Tootsee North area, trenching and ground geophysics to pinpoint structural zones that are highly prospective and would merit drilling. Amy is another high-grade silver-lead-zinc CRD target located just 8 kilometers to the west of the Silvertip mine. The property has a small non-compliant NI 43-101 high grade resource, which cannot be relied to any degree, but maybe an indicator of potential mineralization. High grade silver-lead-zinc mineralization within a limestone unit has also been verified in preliminary sampling efforts at surface by CMC. CMC intends to conduct a detailed mapping of the property and ground geophysics to pinpoint drill targets potentially for a winter drilling program. As previously stated, this deal also provides 100% rights to an additional mineral tenure located in the center of the Amy Property. The assignment of this tenure to CMC in essence removes the "hole of the donut" that existed at the Amy Property. The new tenure now results in total hectares at Amy of 1,038.51 hectares. Mr. Scott retains a 2% Conventional Royalty on the properties which is subject to a $1,000,000 buyout for a 1% interest of the Royalty that can be exercised at any time by CMC.

07:17 EST FSD Pharma says court of appeal dismisses motion for leave to appeal - FSD Pharma announced that the Court of Appeal for Ontario affirmed the Judgment entered by the Superior Court of Justice in the amount of CDN $2.81 million, plus $175,000, plus interest. An additional $5,000 in costs were awarded to FSD Pharma by the Court of Appeal in respect of Dr. Raza Bokhari's failed motion for leave to appeal. The Judgment confirmed Arbitration Awards in which the Arbitrator dismissed Dr. Raza Bokhari's claims for wrongful dismissal, and awarded FSD Pharma its fees and costs incurred in defending the arbitration. In December 2023, FSD Pharma filed a Petition to Confirm Arbitration Awards in the United States District Court for the Eastern District of Pennsylvania. This begins the process by which FSD Pharma will collect from Dr. Raza Bokhari the amounts awarded by the Arbitrator.

07:16 EST Aldebaran Resources continues to expand mineralization at Altar project - Aldebaran Resources reports results from the first four drill holes of the 2023/2024 field campaign at the Altar copper-gold project in San Juan, Argentina. Due to snow constraints at the time of commencing the current field season, three of the holes were significant step-outs to test for the southern extension of mineralization within the large, conductive geophysical anomaly at Altar. As expected, those three holes did not intersect the porphyry intrusive rocks typically associated with the higher-grade mineralization at Altar United, however, they did intersect low- to moderate-grade mineralization in wall rocks that will add resources to a previously undrilled area. Hole ALD-23-234 was designed to test an area in the current resource model that was defined as waste due to lack of drilling. Hole ALD-23-234 successfully hit mineralization and will likely convert waste to resources in the upcoming mineral resource update for the project. Highlights: ALD-23-194EXT: 878.80 m of 0.32% CuEq from 296.00 m depth Including 180.00 m of 0.42% CuEq from 454.00 m depth; Including 36.00 m of 0.77% CuEq from 324.00 m depth. ALD-23-162EXT: 923.10 m of 0.26% CuEq from 356.00 m depth; Including 431.50 m of 0.31% CuEq from 747.00 m depth. ALD-23-166EXT: 773.80 m of 0.24% CuEq from 364.00 m depth. ALD-23-234: 177.10 m of 0.21% CuEq from 83.40 m depth; 728.00 m of 0.20% CuEq from 305.00 m depth. John Black, Chief Executive Officer of Aldebaran, commented as follows: "These first four holes add valuable information to our geological understanding of the Altar project. Holes ALD-23-162EXT, ALD-23-166EXT and ALD-23-194EXT have helped define the southern extents of the Altar United trend, while still adding substantial mineralization to Altar. Hole ALD-23-234 intersected a long run of mineralization in an area previously thought to be waste. This should add substantial value when we transition to a resource update later this year. When we commenced the field campaign in late 2023, our options for drill pad locations were restricted by several areas of the project still having substantial snowfall. We now have access to the entire project and we are currently drilling from more opportune locations to test the extent of the higher-grade mineralization previously encountered in the Altar United Trend and to continue growing the overall mineralized footprint of the Altar project."

07:14 EST Tradeweb Markets boosts dividend 11.1% to 10c per share - The Board of Directors declared a quarterly cash dividend of 10c per share of Class A common stock and Class B common stock, a 11.1% per share increase from prior year. The dividend will be payable on March 15 to stockholders of record as of March 1..

07:14 EST Hepsiburada announces eleven months' results of earthquake region program - D-MARKET Electronic Services & Trading, referred to herein as "Hepsiburada," announces the eleven months' results of its "Trade and Technology Empowerment for the Earthquake Region" program for the period from March 6, 2023 to February 1, 2024. Since the Program's launch in March 2023: The total number of active merchants operating in the earthquake region has reached approximately 16,400 with over 2,800 new businesses selling their products online through Hepsiburada. Active sellers in the earthquake region sold a total of 6.9 million products through 4.4 million orders, generating a trade volume exceeding TRY 3.5 billion. The trade volume generated by 3,299 women entrepreneurs and women's cooperatives reached TRY 272 million. In addition to its E-Commerce Specialization Centers in Adana and Hatay, Hepsiburada plans to open its third center in the first half of 2024. Through the E-Commerce Specialization Centers, Hepsiburada supports existing merchants and organizes training courses and programs for those who are new to the e-commerce market. Over a thousand merchants from the region have benefitted from such training courses. The Company has reached more than 4,000 children in the region through the Program's social responsibility activities. Hepsiburada, in association with the "Promise for Tomorrow Training Program", organized "E-Commerce, Entrepreneurship and Marketing" courses for third and fourth year university students in the provinces affected by the earthquakes. To date, one hundred young people participated in the training program to commemorate the centennial of the Republic of Turkiye. The Program is expected to last for two years as of its inception.

07:12 EST Microbix Biosystems unveils test control for gastric ulcer disease pathogen - Microbix Biosystems announces that it is presenting results of a Quality Assessment Product for supporting the clinical use and accuracy of molecular tests for infection with Helicobacter pylori, the bacterial cause of stomach ulcers, at Labquality Days, a lab diagnostics conference taking place in Helsinki, Finland from February 8 to 10, 2024. Microbix developed its H. pylori QAP to resemble patient specimens, support the whole testing process, and contain all possible MDx test targets - stabilized and dessicated onto a Copan FLOQSwab to ensure stability at room temperature. Pavel Zhelev, lead author of the poster and Microbix's Director of Product Management, commented, "Our growing catalogue of whole-genome and room-temperature stable FLOQSwab-formatted QAPs continue to demonstrate their ability to support quality management on a wide range of molecular assays and instrument platforms - for validation, verification, and training, as external quality assessment samples, for lab QMS support, and as in-kit controls.."

07:10 EST Lithium Ionic reports assay results from Salinas Lithium Project - Lithium Ionic reports assay results from the Salinas Lithium Project, located approximately 100 kilometres north of its Feasibility-stage Bandeira lithium project and the Outro Lado lithium deposit. Blake Hylands, P.Geo., CEO of Lithium Ionic, commented, "These results represent a significant advancement in our drilling has delineated substantial extensions of mineralized pegmatites to the south-west, and the discovery of a new high-grade pegmatite to the North is particularly exciting as it is on trend with the large Lavra do Zoe historical mine working which were exploited over several decades. These findings reinforce the understanding of the mineralized pegmatites at Salinas. Our most recent potential of the Salinas Project to host large scale spodumene pegmatite mineralization."

07:08 EST Plug Power starts production of liquid hydrogen at Tennessee plant - Plug Power has re-started operation of its hydrogen plant in Charleston, Tennessee, adding about ten tons per day of liquid hydrogen supply back onto the U.S. market. Plug also implemented design improvements to enhance overall plant efficiency. Plug's cryogenic trailer fleet will deliver liquid hydrogen from the Tennessee plant to Plug's pedestal customers throughout North America, with a high-density of users clustered throughout the Midwest and along the East Coast. "With the Tennessee plant coming back online, we have taken another step towards building a vertically integrated hydrogen network in North America," said Andy Marsh, Plug Power CEO. "In addition, we expect to have our joint venture plant in Louisiana to come online in the third quarter of 2024, adding another 15 TPD of liquid hydrogen capacity to the market."

07:08 EST Deciphera sees NDA submission for Vimseltinib in 2Q24 - Deciphera expects to submit NDA for Vimseltinib in Q224 and MAA in Q324 in Tenosynovial Giant Cell Tumor TGCT...Results from exploratory ctDNA analysis from INTRIGUE Phase 3 study in 2L GISTpatients with mutations in KIT Exon 11+17/18 published in Nature Medicine; Final overall survival OS results from INTRIGUE study in 2L GIST patients presented at ASCO GI; Cash expected to fund operating and capital expenditures into 2H26...

07:07 EST BioXcel Therapeutics completes patient enrollment in Phase 2 trial of BXCL701 - BioXcel Therapeutics (BTAI) announced the completion of patient enrollment in the safety lead-in portion of the investigator-sponsored Phase 2 trial of BXCL701 in combination with KEYTRUDA in previously treated metastatic pancreatic ductal adenocarcinoma, PDAC. BioXcel Therapeutics, through its OnkosXcel Therapeutics immuno-oncology subsidiary, is collaborating with Georgetown Lombardi's Dr. Louis Weiner, director of the cancer center, and Dr. Benjamin Weinberg, the study's principal investigator. BioXcel Therapeutics and Merck & Co. (MRK) are providing BXCL701 and KEYTRUDA for the trial, respectively. "Pancreatic cancer represents a significant unmet medical need, ranking as the third-leading cause of cancer deaths, yet remains an exceptionally difficult cancer to treat. No novel therapies have emerged in decades, and overall survival for advanced disease has not improved in over 10 years," said Dr. Weiner. "Building on results from the preclinical work conducted in our lab, we are excited to evaluate BXCL701 in this important trial as a potential treatment for advanced pancreatic cancer."

07:05 EST Helius Medical announces alignment with FDA on registrational program - Helius Medical Technologies announced that it has concluded its interaction with the U.S. Food and Drug Administration, FDA, on optimizing the development plan for its stroke program which aims to evaluate the effects of cranial-nerve non-invasive neuromodulation, CN-NINM, delivered using PoNS Therapy on gait and dynamic balance in chronic stroke survivors. Helius' registrational program includes two controlled studies. The clinical program will leverage a randomized, controlled, double blinded investigator-initiated trial, led by Dr. Steven Kautz at the Medical University of South Carolina and a Company-sponsored study to enroll approximately 100 subjects. Dr. Kautz's IIT began enrollment of 60 participants in September 2023 with the collaboration of Dr. Mark Bowden at Brooks Rehabilitation as a second site. "Vetting the registrational program and design of our clinical studies with the FDA is an important milestone for Helius and meeting the agency's expectations will give us the most efficient path to delivering PoNS Therapy to stroke patients," said Dr. Antonella Favit-Van Pelt, Helius' Chief Medical Officer. "This development plan, which leverages early study results and real-world evidence from Canada, allows us to streamline the size, timeline, and cost of the registrational program and positions Helius on the best course toward potential FDA authorization under PoNS's breakthrough designation for stroke."

07:03 EST LMP Automotive to issue shareholder liquidation distribution of 20c per share - LMP Automotive Holdings will issue a liquidating shareholder distribution of $0.20 per share on or about February 7, 2024, to all shareholders of record as of January 31, 2024 and provided a corporate update. The Company further announced that it's Chairman and Chief Executive Officer Sam Tawfik agreed to provide his management services to the Company without compensation commencing after March 1, 2024, and hold perfunctory office until expiration of Delaware dissolution period, filing of final Tax Returns and final Distributions, if any, are made. After the payment of the final dissolution costs and the resolution of any contingent, conditional or unmatured contractual claims of the Company, the Company anticipates that it will make another liquidating distribution to its shareholders payable upon surrender of the shares. Although the Company cannot project how much cash, if any, will remain after the completion of the final dissolution, the Company expects to issue one or more liquidating distributions, estimated to be in the second half of 2024, and ranging between $0.02 to $0.36 to its shareholders, which will be substantially comprised of an anticipated Income Tax Refund and potential Employee Retention Credits.

06:54 EST Consol Energy sees FY24 capital expenditures $175M-$200M

06:52 EST PJT Partners announces $500M share repurchase program - On February 5, 2024, the company's Board of Directors authorized a $500M repurchase program of the company's Class A common stock. This authorization replaces the existing repurchase program authorized on April 25, 2022.

06:49 EST Arvinas, Pfizer: FDA grants Fast Track designation for ARV-471 - Arvinas (ARVN) and Pfizer (PFE) announced that the U.S. FDA has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor positive/human growth epidermal growth factor 2 negative locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Vepdegestrant is a novel oral PROteolysis Targeting Chimera ER degrader that is being jointly developed by Arvinas and Pfizer.

06:48 EST BP intends to execute further $1.75B share buyback - The company said, "A resilient dividend is bp's first priority within its disciplined financial frame, underpinned by a cash balance point of around $40 per barrel Brent, $11 per barrel RMM and $3 per mmBtu Henry Hub. For the fourth quarter, bp has announced a dividend per ordinary share of 7.270 cents, up 10% from the fourth quarter of 2022. bp continues to invest with discipline and a returns focused approach in our transition growth engines and in our oil, gas and refining businesses. For 2024 and 2025 we expect capital expenditure of around $16 billion per annum, in line with our medium term target of $14-18 billion. Related to the fourth quarter results, bp intends to execute a $1.75 billion share buyback prior to reporting first quarter results. Furthermore, bp is committed to announcing $3.5 billion for the first half of 2024. At current market conditions and subject to maintaining a strong investment grade credit rating, bp plans share buybacks of at least $14 billion through 2025 as part of our commitment, on a point forward basis, to returning at least 80% of surplus cash flow to shareholders."

06:45 EST Jacobs increases quarterly dividend 11.5%

06:37 EST UBS expects Q1 revenues to be 'positively influenced' by seasonal factors - "Central banks are widely expected to lower short-term interest rates in 2024. The timing and magnitude of such cuts are still highly uncertain, given the ongoing debate around the pace of inflation converging with central bank targets. In addition, ongoing geopolitical tensions, including the conflicts in the Middle East and Eastern Europe, may impact supply chains and inflation, with consequences for the macroeconomic outlook and market volatility. Notwithstanding the challenges mentioned above, we continue to execute on our strategy and integration plans at pace, and we will actively reduce non-core assets and costs. In the first quarter of 2024, we expect revenues to be positively influenced by seasonal factors, such as higher client activity levels compared with the fourth quarter of 2023. We also expect the Investment Bank to return to profitability, due to improving market activity, a growing banking pipeline and advanced progress on the integration. We expect NII for Personal & Corporate Banking and Global Wealth Management combined, and in US dollar terms, to be roughly flat sequentially in the first quarter, with higher rates broadly offsetting the residual effects of deposit mix shifts and the initial impact of financial resource optimization. These factors are expected to result in substantial sequential improvement in reported net profit in the first quarter, including around USD 1bn of integration-related expenses and around USD 0.7bn of pull to par and other purchase price allocation accretion effects. Our focus remains on helping clients navigate challenging market environments to manage the inherent risks and opportunities while continuing to grow our invested assets and delivering on our financial targets.

06:33 EST UBS reiterates 15% underlying RoCET1 target by end of 2026 - In it's investor update highlights, UBS said, "Re-iterating ~15% underlying RoCET1 and less than70% underlying cost/income ratio exit rate targets by end-2026; well positioned to deliver long-term growth and higher returns with ~18% reported RoCET1 in 2028; Targeting USD ~13bn gross cost reductions by end-2026; ~50% of cumulative exit rate gross cost reductions expected by end-2024; Cost savings to provide necessary capacity for reinvestment to reinforce the resilience of our combined infrastructure as we absorb Credit Suisse and to drive sustainable growth; Ambition to surpass USD 5trn of invested assets in GWM by 2028, with USD ~100bn of NNA per annum through 2025, building to USD ~200bn per annum by 2028; NCL actively run down; underlying operating expenses expected to be USD less than1bn and underlying loss before tax expected to be USD ~1bn by end-2026; RWA expected to be around 5% of Group RWA; Optimizing financial resources to enable sustainable growth and higher returns; USD ~510bn of RWA expected by end-2026; expecting USD ~45bn of RWA reductions in NCL and USD ~15bn of business-led RWA reductions in core divisions from actions to improve capital efficiency; Basel 3 finalization and migrating Credit Suisse's portfolios to UBS risk models are expected to increase RWAs in the core divisions by USD 25bn; Expecting up to USD 1bn of funding cost saves by 2026 relative to 2023 levels as a result of lower funding needs, diversified and more stable funding sources, and disciplined deposit pricing; Merger of UBS AG and Credit Suisse AG planned to be completed by the end of 2Q24 and merger of UBS Switzerland AG and Credit Suisse AG entities planned before the end of 3Q24, which is a critical step in enabling us to unlock the next phase of the cost, capital and funding synergies we expect to realize in 2025 and 2026; Delivering attractive capital returns; planning to reinstate share repurchases after completion of UBS AG and Credit Suisse AG merger, with up to USD 1bn in 2024, committed to progressive dividends and accruing for a mid-teen percentage increase in the dividend per share for 2024; ambition for FY26 share repurchases to exceed FY22 levels."

06:23 EST Toyota sees FY24 group vehicle sales 11.23M units

06:17 EST U Power signs MoU with Cornerstone to explore new energy charging equipment - U Power announced that it has signed a memorandum of understanding, or MoU, with Cornerstone Technologies, a EV charging solution provider and charge point operator based in Hong Kong, to jointly explore and develop a strategic business relationship. Pursuant to the MoU, U Power and Cornerstone intend to jointly assess and promote the application of new energy charging equipment and EV product solutions, such as battery swapping stations and other charging equipment to provide effective and sustainable solutions in Hong Kong and the Southeast Asia region. In addition, both parties have agreed to explore the possibility of investing into a joint venture for the business.

06:12 EST GSK says application accepted under FDA Priority Review for RSV vaccine - GSK plc announced that the U.S. Food and Drug Administration has accepted under Priority Review an application to extend the indication of GSK's adjuvanted respiratory syncytial virus, or RSV, vaccine to adults aged 50-59 who are at increased risk for RSV disease. "If approved, GSK's RSV vaccine would be the first vaccine available to help protect this population. Arexvy is currently approved in the US in adults aged 60 and over for the prevention of lower respiratory tract disease caused by RSV," the company stated. GSK used a Priority Review Voucher to reduce the U.S. FDA review period of a supplemental Biologics License Application, or sBLA, by four months. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is June 7, 2024.

06:10 EST Nintendo reports 9M hardware units sold 13.74M, down 7.8% y-o-y - The company said, "Regarding the Nintendo Switch business during the nine months ended December 31, 2023, Super Mario Bros. Wonder, the first entirely new installment in the side-scrolling Super Mario Bros. series in almost 11 years, saw a solid start with sales of 11.96 million units. Sales also grew for other new titles released this fiscal year, with The Legend of Zelda: Tears of the Kingdom selling 20.28 million units and Pikmin 4 selling 3.33 million units. In addition, the April release of The Super Mario Bros. Movie positively impacted sales of Mario related titles, such as Mario Kart 8 Deluxe which recorded sales of 6.79 million units. As a result of these factors, the total number of million-seller titles during this period was 24, including titles from other software publishers. Sales of Nintendo Switch continued to be steady in the seventh year since its launch, with hardware sales totaling 13.74 million units, a decrease of 7.8% year-on-year, and software sales totaling 163.95 million units, for the period.Turning to the digital business for our dedicated video game platform, downloadable versions of packaged software and add-on content for Nintendo Switch sold well, and sales related to Nintendo Switch Online also increased. Digital sales reached 346.4billion yen, up 11.7% year-on-year, helped also by the depreciation of the yen. In the mobile and IP related business, sales totaled 75.2 billion yen, bolstered mainly by the generation of revenue related to The Super Mario Bros. Movie during this term. The end result is that overall sales reached 1,394.7 billion yen, with sales outside Japan of 1,097.5 billion yen accounting for 78.7% of the total. Operating profit came to 464.4 billion yen, ordinary profit was 567.3 billion yen, and profit attributable to owners of parent totaled 408.0 billion yen."

06:07 EST DuPont announces new $1B share repurchase program - DuPont announced completion of the $2B accelerated share repurchase, or ASR, transaction launched in September 2023 which completes its $5B share repurchase program announced in November 2022. In connection with completion of the $2B ASR transaction, DuPont received and retired in the first quarter of 2024 an additional 6.7M shares of its common stock. In total for the $2B ASR transaction, DuPont received and retired 27.9M shares of its common stock. Additionally, DuPont announced that its board of directors approved a new share repurchase program authorizing the repurchase and retirement of up to $1B of common stock. DuPont intends to enter into ASR transactions under the $1B Program beginning with an ASR transaction expected to be launched imminently to repurchase in aggregate $500 million of common stock. DuPont expects to complete the $1B Program by the end of 2024. Under the $1B Program, repurchases may be made from time to time on the open market at prevailing market prices or in privately negotiated transactions off market. The $1B Program terminates on June 30, 2025, unless extended or shortened by the Board of Directors. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements.

06:02 EST RTX discloses SEC subpoenas related to engine recall - In a regulatory filing, RTX disclosed that on November 7, 2023 and January 30, 2024, the company received subpoenas from the SEC seeking engineering, operational, organizational, accounting, and financial documents in connection with an investigation relating to the company's disclosures in 2023 of issues arising from Pratt & Whitney's use of powder metal in manufacturing various engine parts, its identification of certain risks associated with those manufacturing processes, and corrective actions identified by Pratt & Whitney to mitigate those risks. The company is cooperating with the SEC and is responding to the subpoenas.

05:37 EST Western Digital, Kioxia Corporation jv facilities to receive 150B yen subsidy - Kioxia Corporation and Western Digital announced that their joint venture manufacturing facilities at Yokkaichi and Kitakami plants have been approved to receive an up to 150B yen subsidy, including facilities that will produce its latest generation of 3D flash memory based on the innovative wafer bonding technology and future generation advanced nodes. The subsidy will be granted under a designated government program aimed at facilitating corporate investment in cutting-edge semiconductor production facilities and securing stable production of semiconductors in Japan. This marks the second time that Kioxia's and Western Digital's joint venture manufacturing facilities are receiving this subsidy from the Japanese government. Previously, the joint venture manufacturing facility at Yokkaichi was approved to receive up to 92.9B yen subsidy from the Japanese government in 2022. Leveraging an over 20-year joint venture partnership, Kioxia and Western Digital will continue to enhance the development and production capabilities of cutting-edge flash memory at the Yokkaichi and Kitakami plants in Japan. In addition, the two companies will contribute to the development of semiconductor-related industries and talent.

05:27 EST AudioCodes declares 18c per share cash dividend - AudioCodes also announced that the company's board of directors has declared a cash dividend in the amount of 18c per share. The aggregate amount of the dividend is approximately $5.5M. The dividend is payable on March 6 to all of the company's shareholders of record at the close of trading on the Nasdaq Global Select Market on February 20. In accordance with Israeli tax law, the dividend is subject to withholding tax at source at the rate of 25% of the dividend amount payable to each shareholder of record, subject to applicable exemptions.

05:14 EST JinkoSolar announces TOPCon patent license agreement - JinkoSolar announced its affiliated company has recently signed a TOPCon patent license agreement with one of the world's top five solar cell companies, granting rights to certain of its N-type TOPCon related patents to Licensee for a fee, allowing Licensee to use certain JinkoSolar's patented TOPCon technologies in its relevant TOPCon products. This agreement follows the agreement signed with one of the world's top ten solar module companies as announced on January 5. With one of the largest number of granted N-type TOPCon patents, JinkoSolar is a leader in N-type TOPCon technology. The company is fully focused on sustaining its technical leadership based on its extensive intellectual property rights.